Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Suppression effect on IFN-γ of adipose tissue-derived mesenchymal stem cells isolated from β2-microglobulin-deficient mice.

Masuda J, Takayama E, Ichinohe T, Strober W, Mizuno-Kamiya M, Ikawa T, Kitani A, Kawaki H, Fuss I, Kawamoto H, Seno A, Vaidyanath A, Umemura N, Mizutani A, Kasai T, Honjo Y, Satoh A, Murakami H, Katsura Y, Kondoh N, Seno M.

Exp Ther Med. 2018 Nov;16(5):4277-4282. doi: 10.3892/etm.2018.6689. Epub 2018 Sep 4.

2.

Anodic reactions of NADH model compound by utilizing both light irradiation and riboflavin as a redox mediator.

Yano J, Suzuki K, Tsutsumi C, Mabuchi M, Hayase N, Kitani A.

Biosci Biotechnol Biochem. 2018 Nov;82(11):1849-1854. doi: 10.1080/09168451.2018.1505483. Epub 2018 Aug 10.

PMID:
30096048
3.

Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2- Early-stage Breast Cancer.

Kuwayama T, Nakamura S, Hayashi N, Takano T, Tsugawa K, Sato T, Kitani A, Okuyama H, Yamauchi H.

Clin Breast Cancer. 2018 Jun 27. pii: S1526-8209(16)30572-9. doi: 10.1016/j.clbc.2018.06.012. [Epub ahead of print]

PMID:
30072191
4.

An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis.

Takagawa T, Kitani A, Fuss I, Levine B, Brant SR, Peter I, Tajima M, Nakamura S, Strober W.

Sci Transl Med. 2018 Jun 6;10(444). pii: eaan8162. doi: 10.1126/scitranslmed.aan8162.

PMID:
29875204
5.

Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease.

Mao L, Kitani A, Similuk M, Oler AJ, Albenberg L, Kelsen J, Aktay A, Quezado M, Yao M, Montgomery-Recht K, Fuss IJ, Strober W.

J Clin Invest. 2018 May 1;128(5):1793-1806. doi: 10.1172/JCI98642. Epub 2018 Mar 26.

6.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H.

Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11.

PMID:
28895005
7.

Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities.

Masuda J, Takayama E, Strober W, Satoh A, Morimoto Y, Honjo Y, Ichinohe T, Tokuno SI, Ishizuka T, Nakata T, Mizutani A, Umemura N, Kitani A, Fuss IJ, Shigehiro T, Kawaki H, Mizuno-Kamiya M, Kondoh N, Seno M.

Oncol Rep. 2017 Jul;38(1):449-455. doi: 10.3892/or.2017.5646. Epub 2017 May 17.

PMID:
28535011
8.

Transient Tcf3 Gene Repression by TALE-Transcription Factor Targeting.

Masuda J, Kawamoto H, Strober W, Takayama E, Mizutani A, Murakami H, Ikawa T, Kitani A, Maeno N, Shigehiro T, Satoh A, Seno A, Arun V, Kasai T, Fuss IJ, Katsura Y, Seno M.

Appl Biochem Biotechnol. 2016 Dec;180(8):1559-1573. Epub 2016 Jul 12.

PMID:
27406037
9.

Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.

Strober W, Asano N, Fuss I, Kitani A, Watanabe T.

Immunol Rev. 2014 Jul;260(1):249-60. doi: 10.1111/imr.12193. Review.

PMID:
24942694
10.

NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6.

Watanabe T, Asano N, Meng G, Yamashita K, Arai Y, Sakurai T, Kudo M, Fuss IJ, Kitani A, Shimosegawa T, Chiba T, Strober W.

Mucosal Immunol. 2014 Nov;7(6):1312-25. doi: 10.1038/mi.2014.19. Epub 2014 Mar 26.

11.

IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3β.

Fichtner-Feigl S, Kesselring R, Martin M, Obermeier F, Ruemmele P, Kitani A, Brunner SM, Haimerl M, Geissler EK, Strober W, Schlitt HJ.

J Immunol. 2014 Apr 15;192(8):3969-80. doi: 10.4049/jimmunol.1301072. Epub 2014 Mar 14.

12.

NOD1-Mediated Mucosal Host Defense against Helicobacter pylori.

Watanabe T, Asano N, Kitani A, Fuss IJ, Chiba T, Strober W.

Int J Inflam. 2010 Jul 15;2010:476482. doi: 10.4061/2010/476482.

13.

Efficient in vivo delivery of plasmids and oligonucleotides using hemagglutinating virus of Japan envelope (HVJ-E) vector in immunological disease models.

Kitani A, Fichtner-Feigl S.

Curr Protoc Immunol. 2010 Nov;Chapter 10:Unit 10.17E.1-9. doi: 10.1002/0471142735.im1017es91.

PMID:
21053301
14.

Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I.

Xu L, Kitani A, Stuelten C, McGrady G, Fuss I, Strober W.

Immunity. 2010 Sep 24;33(3):313-25. doi: 10.1016/j.immuni.2010.09.001.

15.

Proinflammatory cytokines underlying the inflammation of Crohn's disease.

Strober W, Zhang F, Kitani A, Fuss I, Fichtner-Feigl S.

Curr Opin Gastroenterol. 2010 Jul;26(4):310-7. doi: 10.1097/MOG.0b013e328339d099.

16.

Molecular mechanisms regulating TGF-beta-induced Foxp3 expression.

Xu L, Kitani A, Strober W.

Mucosal Immunol. 2010 May;3(3):230-8. doi: 10.1038/mi.2010.7. Epub 2010 Mar 10. Review.

17.

NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway.

Watanabe T, Asano N, Fichtner-Feigl S, Gorelick PL, Tsuji Y, Matsumoto Y, Chiba T, Fuss IJ, Kitani A, Strober W.

J Clin Invest. 2010 May;120(5):1645-62. doi: 10.1172/JCI39481. Epub 2010 Apr 12.

18.

Activation of type I IFN signaling by NOD1 mediates mucosal host defense against Helicobacter pylori infection.

Watanabe T, Asano N, Kitani A, Fuss IJ, Chiba T, Strober W.

Gut Microbes. 2011 Jan-Feb;2(1):61-5. doi: 10.4161/gmic.2.1.15162. Review.

19.

The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance.

Strober W, Kitani A, Fichtner-Feigl S, Fuss IJ.

Curr Mol Med. 2009 Aug;9(6):740-50. Review.

PMID:
19689301
20.

A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses.

Meng G, Zhang F, Fuss I, Kitani A, Strober W.

Immunity. 2009 Jun 19;30(6):860-74. doi: 10.1016/j.immuni.2009.04.012. Epub 2009 Jun 4.

21.

The molecular basis of NOD2 susceptibility mutations in Crohn's disease.

Strober W, Kitani A, Fuss I, Asano N, Watanabe T.

Mucosal Immunol. 2008 Nov;1 Suppl 1:S5-9. doi: 10.1038/mi.2008.42. Review.

22.

Regulatory T cells and the induction of IL-17.

Kitani A, Xu L.

Mucosal Immunol. 2008 Nov;1 Suppl 1:S43-6. doi: 10.1038/mi.2008.51. Review.

PMID:
19079228
23.

IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis.

Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W.

Gastroenterology. 2008 Dec;135(6):2003-13, 2013.e1-7. doi: 10.1053/j.gastro.2008.08.055. Epub 2008 Sep 11.

PMID:
18938165
24.

Evaluation of quality of life and psychological response in cancer patients treated with radiotherapy.

Takahashi T, Hondo M, Nishimura K, Kitani A, Yamano T, Yanagita H, Osada H, Shinbo M, Honda N.

Radiat Med. 2008 Aug;26(7):396-401. doi: 10.1007/s11604-008-0248-5. Epub 2008 Sep 4.

PMID:
18769996
25.

A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis.

Boirivant M, Amendola A, Butera A, Sanchez M, Xu L, Marinaro M, Kitani A, Di Giacinto C, Strober W, Fuss IJ.

Gastroenterology. 2008 Nov;135(5):1612-1623.e5. doi: 10.1053/j.gastro.2008.07.028. Epub 2008 Aug 5.

PMID:
18765239
26.

Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.

Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W.

Cancer Res. 2008 May 1;68(9):3467-75. doi: 10.1158/0008-5472.CAN-07-5301.

27.

Notch1 signaling and regulatory T cell function.

Asano N, Watanabe T, Kitani A, Fuss IJ, Strober W.

J Immunol. 2008 Mar 1;180(5):2796-804.

28.

Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.

Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, Fuss IJ, Kitani A, Strober W.

J Clin Invest. 2008 Feb;118(2):545-59. doi: 10.1172/JCI33145.

29.

NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction.

Yang Z, Fuss IJ, Watanabe T, Asano N, Davey MP, Rosenbaum JT, Strober W, Kitani A.

Gastroenterology. 2007 Nov;133(5):1510-21. Epub 2007 Jul 25.

31.

Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis.

Fichtner-Feigl S, Fuss IJ, Young CA, Watanabe T, Geissler EK, Schlitt HJ, Kitani A, Strober W.

J Immunol. 2007 May 1;178(9):5859-70.

32.

Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis.

Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W.

Immunity. 2006 Sep;25(3):473-85. Epub 2006 Aug 31.

33.

TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling.

Oida T, Xu L, Weiner HL, Kitani A, Strober W.

J Immunol. 2006 Aug 15;177(4):2331-9.

34.

Signalling pathways and molecular interactions of NOD1 and NOD2.

Strober W, Murray PJ, Kitani A, Watanabe T.

Nat Rev Immunol. 2006 Jan;6(1):9-20. Review.

PMID:
16493424
35.

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis.

Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A.

Nat Med. 2006 Jan;12(1):99-106. Epub 2005 Dec 4.

PMID:
16327802
36.

Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.

Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A.

J Clin Invest. 2005 Nov;115(11):3057-71. Epub 2005 Oct 20.

37.

NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease.

Watanabe T, Kitani A, Strober W.

Gut. 2005 Nov;54(11):1515-8. Review. No abstract available.

38.

Insights into the mechanism of oral tolerance derived from the study of models of mucosal inflammation.

Strober W, Fuss I, Boirivant M, Kitani A.

Ann N Y Acad Sci. 2004 Dec;1029:115-31. Review.

PMID:
15681751
39.

NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Watanabe T, Kitani A, Murray PJ, Strober W.

Nat Immunol. 2004 Aug;5(8):800-8. Epub 2004 Jun 27.

40.

Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W.

J Clin Invest. 2004 May;113(10):1490-7.

41.

TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice.

Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W.

J Immunol. 2004 Jan 15;172(2):834-42.

43.
44.

Intermolecular hydrophosphination of alkynes and related carbon[bond]carbon multiple bonds catalyzed by organoytterbiums.

Takaki K, Koshoji G, Komeyama K, Takeda M, Shishido T, Kitani A, Takehira K.

J Org Chem. 2003 Aug 22;68(17):6554-65.

PMID:
12919015
45.

Recent advances in the understanding of the induction and regulation of mucosal inflammation.

Strober W, Fuss IJ, Nakamura K, Kitani A.

J Gastroenterol. 2003 Mar;38 Suppl 15:55-8. Review. No abstract available.

PMID:
12698873
46.
47.

Regulation of experimental mucosal inflammation.

Strober W, Fuss I, Kitani A.

Acta Odontol Scand. 2001 Aug;59(4):244-7.

PMID:
11570528
49.

The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease.

Strober W, Nakamura K, Kitani A.

J Clin Invest. 2001 Mar;107(6):667-70. Review. No abstract available.

Supplemental Content

Loading ...
Support Center